Results 51 to 60 of about 8,272 (178)

Mesenchymal stromal cell therapy for rheumatoid arthritis: Long‐term efficacy, safety, and mechanistic insights

Rheumatology &Autoimmunity, EarlyView.
Graphical abstract summarizing the multifactorial pathogenesis of rheumatoid arthritis (RA) and the therapeutic potential of mesenchymal stromal cell (MSC) therapy. MSCs provide promising benefits through their immunomodulatory properties, low immunogenicity, ability to promote tissue repair, and multi‐lineage differentiation, presenting a potential ...
Yingjia Chen, Ruiyu Gao, Xing Guo, Genhong Yao, Xiaojun Tang, Yile E. Liu, Lingyun Sun   +6 more
wiley   +1 more source

Germ line origin and somatic mutations determine the target tissues in systemic AL-amyloidosis. [PDF]

PLoS ONE, 2007
BACKGROUND: Amyloid is insoluble aggregated proteins deposited in the extra cellular space. About 25 different proteins are known to form amyloid in vivo and are associated with severe diseases such as Alzheimer's disease, prion diseases and type-2 ...
Stina Enqvist, Knut Sletten, Fred J Stevens, Ulf Hellman, Per Westermark   +4 more
doaj   +1 more source

Utilization and Prognosis of Cardiac Device Implantation in AL Versus ATTR Amyloidosis

Pacing and Clinical Electrophysiology, EarlyView.
ABSTRACT Introduction Cardiac amyloidosis can cause congestive heart failure, arrhythmias, and heart blocks, which frequently require cardiac device implantation (CDI). However, the differences between light chain (AL) amyloidosis and transthyretin (ATTR) amyloidosis CDI requirements are unknown. Methods A retrospective analysis was conducted using the
Bilal Hussain, Sanchit Duhan, Khawaja Hassan Akhtar, Amith Reddy Seri, Krittapoom Akrawinthawong, Janardhana Gorthi, Bijeta Keisham, Tarun Dasari   +7 more
wiley   +1 more source

Systemic Immunoglobulin Light Chain Amyloidosis Presenting as Painful Penile Ulcers

Annals of Internal Medicine: Clinical Cases, 2022
Immunoglobulin light chain (AL) amyloidosis is a systemic form of amyloidosis that commonly affects the heart, kidney, liver, and nervous system. Penile involvement in AL amyloidosis is rare and thus often not considered in the differential diagnosis for
Crystal Lihong Yan, Fireneh N. Beshah, Karen Eliahu, James E. Hoffman   +3 more
doaj   +1 more source

Localized Gastrointestinal Light Chain (AL) Amyloidosis Under Surveillance for Five Years: A Case Report

DEN Open, Volume 7, Issue 1, April 2027.
ABSTRACT Amyloidosis, characterized by the deposition of abnormal protein fibrils in organs, is classified as systemic or localized. Amyloid light chain (AL)‐type localized amyloidosis is uncommon, particularly when confined to the gastrointestinal tract.
Shunsuke Kojimahara, Keiichi Tominaga, Akira Yamamiya, Mimari Kanazawa, Takanao Tanaka, Takeshi Sugaya, Nagaaki Katoh, Atsushi Irisawa   +7 more
wiley   +1 more source

Clinical Practice Guideline for Evaluation and Management of Peripheral Nervous System Manifestations in Sjögren's Disease

Arthritis Care &Research, Volume 78, Issue 7, Page 860-874, July 2026.
Objective Sjögren's disease is an autoimmune disorder that can impact multiple organ systems, including the peripheral nervous system (PNS). PNS manifestations, which can exist concurrently, include mononeuropathies, polyneuropathies, and autonomic nervous system neuropathies.
Anahita Deboo, Robert Fox, Katherine M. Hammitt, Julie Frantsve‐Hawley, Matthew C. Baker, Stamatina Danielides, Eduardo De Sousa, Brent P. Goodman, Jennifer K. King, Steven Mandel, Ghaith Noaiseh, Pantelis P. Pavlakis, George Sarka, R. Hal Scofield, Arun Varadhachary, Daniel J. Wallace, Matt Makara, Nancy Carteron, Steven Carsons, in collaboration with the Consensus Expert Panel (CEP) members, G. Alden Adkins, Brittany Adler, Hossein Ansari, Senada Arabelovic, Alan Baer, Denis Balaban, Shamik Bhattacharyya, Evelyn Bromet, Krishna Chaganti, Kamal Chemali, Melissa Cortez, Schartess Culpepper, Paul Dellaripa, Dana Direnzo, Daniel El Bogdadi, Robert Fearon, Mehrnez Fischbach, Judi Furlong, Christopher Gibbons, Rachael Gordon, Thomas Grader Beck, Syed Haider, Larry Hollenbeck, Chadwick R. Johr, Stuart S. Kassan, Brian King, Octavia Kincaid, Eugene Kissin, Vasileios Kyttaris, Lindsay Lally, Brandon M. Law, Janet Lewis, Scott M. Lieberman, Amanda Lusa, Joseph Lutt, Rashmi Maganti, Arthur M. Mandelin, Sara McCoy, Kerry Neall, Timothy Niewold, Anne Louise Oaklander, Ruben A. Peredo‐Wende, Lynn Petruzzi, Mark A. Porter, Guada Respicio Duque, Tania Reyna, Nathaniel M. Robbins, Elliot D. Rosenstein, Laura Rosow, Breanna Ruthrauff, Amit Sachdev, Nora Sandorfi, Sarah Schafer, Elena Schiopu, Chokkalingam Siva, Daniel Small, Sara M. Stern, Lauren Stiles, Susan Stoddard, Jinny Tavee, Donald Thomas, Edward L. Treadwell, Nagagopal Venna, Steven Vernino, Frederick B. Vivino, Brittany Weber, Sepideh Yadollahi, Huiying Yu, Scott Zashin   +88 more
wiley   +1 more source

Endogenously generated Dutch‐type Aβ non‐fibrillar aggregates dysregulate presynaptic neurotransmission in the absence of detectable inflammation

Alzheimer's &Dementia, Volume 22, Issue 6, June 2026.
Abstract BACKGROUND APPE693Q (“Dutch”) transgenic mice develop aging‐related learning deficits and accumulate endogenously generated non‐fibrillar aggregates (NFAs) of amyloid beta (Aβ) and amyloid precursor protein α‐carboxy terminal fragments. NFA‐Aβ correlates with synaptic loss and memory deficits more closely than does fibrillar Aβ.
Emilie L. Castranio, Merina Varghese, Elentina K. Argyrousi, Kuldeep Tripathi, Yong Huang, Akiko Asada, Linda Söderberg, Erin Bresnahan, David Lerner, Francesca Garretti, Hong Zhang, Jonathan van de Loo, Cheryl D. Stimpson, Ronan Talty, Charles Glabe, Efrat Levy, Minghui Wang, Marjan Ilkov, Toshiharu Suzuki, Kanae Ando, Bin Zhang, Lars Lannfelt, Brigitte Guérin, William D. Lubell, Shai Rahimipour, Dara L. Dickstein, Sam Gandy, Ottavio Arancio, Michelle E. Ehrlich   +28 more
wiley   +1 more source

Critical Management Strategies for Cardiovascular Involvementin Light Chain Amyloidosis

罕见病研究, 2023
Light chain amyloidosis (AL) is a kind of rare disease. The misfolding of the light chain of monoclonal immunoglobulin forms amyloid substances and deposit in different tissues and organs, resulting in organ dysfunction.
SHI Yunjing, JIN Wei
doaj   +1 more source

Long‐Term Outcomes of Reduced‐Intensity Conditioning Hematopoietic Stem Cell Transplantation for Patients With Systemic Sclerosis With Impaired Cardiac Function

Arthritis &Rheumatology, Volume 78, Issue 6, Page 1294-1305, June 2026.
Objective High‐intensity conditioning autologous hematopoietic stem cell transplantation (AHSCT) is standard of care for patients with advanced systemic sclerosis (SSc). The role of reduced‐intensity conditioning (RIC) before AHSCT in this population remains unclear.
Yonatan Lean, Carrie Richardson, Anthony J. Esposito, Katy Bedjeti, George E. Georges   +4 more
wiley   +1 more source

Diagnosing Smoldering Multiple Myeloma and Light Chain Amyloidosis in the Setting of Severe Transthyretin Amyloid Cardiomyopathy and Extracardiac Sarcoidosis

Annals of Internal Medicine: Clinical Cases
Light chain (AL) amyloidosis involves deposition of monoclonal immunoglobulin light chain-derived amyloid fibrils, whereas ATTR amyloidosis involves deposition of insoluble antiparallel beta-pleated protein within tissues, leading to organ-specific ...
Robert A. Churchill, Andrew Rosenbaum
doaj   +1 more source